Healthcare Leaders Hub

🏠Home 📰News 📝Blog 🎬Videos Advertise Login

Your trusted source for pharmaceutical news, expert insights, and healthcare innovation.

💼𝕏 👥▶️

Content

📰News
📝Blog
🎬Videos

Company

🏠Home
🏢About Us
📧Contact

© 2026 PharmaVoice. All rights reserved. Empowering healthcare leaders.

Privacy Policy•Terms of Service

Pharma Tech

FDA grants fast track designation for Lundbeck’s Lu AH69593

Jul 24, 2026, 8:40 AM

Read Full Article → FDA grants fast track designation for Lundbeck’s Lu AH69593

FDA grants fast track designation for Lundbeck’s Lu AH69593

Translate article text

Choose a language and wait for the translated text.

Lundbeck has secured fast track designation from the US FDA for its investigational treatment, Lu AH69593, to treat narcolepsy.

FDA grants fast track designation for Lundbeck’s Lu AH69593 | PharmaVoice